U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula S.Zn
Molecular Weight 97.474
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ZINC SULFIDE

SMILES

[S--].[Zn++]

InChI

InChIKey=DRDVZXDWVBGGMH-UHFFFAOYSA-N
InChI=1S/S.Zn/q-2;+2

HIDE SMILES / InChI
Molecular Formula HS
Molecular Weight 33.073
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula Zn
Molecular Weight 65.409
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125327s020lbl.pdfhttps://www.ewg.org/skindeep/ingredient/724913/ZINC_CARBONATE/# | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=582.80 | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=347.10 | https://www.ncbi.nlm.nih.gov/pubmed/10378806 | https://www.ncbi.nlm.nih.gov/pubmed/17633459https://www.drugs.com/mtm/zinc-oxide-topical.htmlhttp://www.hmdb.ca/metabolites/HMDB01303http://www.t3db.ca/toxins/T3D0733https://www.google.com/patents/US3130034http://www.chemistrylearner.com/zinc-hydroxide.html | http://www.lookchem.com/Zinc-hydroxide/http://www.azom.com/article.aspx?ArticleID=8415 | https://www.accessdata.fda.gov/scripts/fdcc/?set=IndirectAdditives&id=ZINCSULFIDE | http://www.imse.iastate.edu/files/2014/03/Jianqiang_Li_Master_Thesis.pdf | https://www.ncbi.nlm.nih.gov/pubmed/24477783http://www.npi.gov.au/resource/zinc-and-compounds | https://www.ncbi.nlm.nih.gov/pubmed/27546855 | https://www.ncbi.nlm.nih.gov/pubmed/6353570
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/6309044

Zinc fluoride (ZnF2) is used in the fluorination of organic compounds, in the manufacturing of phosphors for fluorescent lights, in preserving wood, in electroplating baths, in galvanising steel, and making ceramics. It is also used as a termite repellent, in medication, and in glazes and enamels for porcelain. Zn compounds have been used as active ingredients in dentifrice for anti-calculus, antimicrobial/gingivitis, and anti-malodor for a long time. ZnF2/HCl might have potential benefit as a staining-free agent to tooth substrate for root caries prevention. It has being shown to have antiplaque and caries preventive effects. Zinc fluoride protects enamel, dentine and the root area against caries.

CNS Activity

Originator

Smithson, R.
38
Curator's Comment: Centuries before zinc was recognized as a distinct element, zinc ores were used for making brass (a mixture of copper and zinc). A brass dating from between 1400-1000 BC has been found in Palestine. An alloy containing 87% zinc was found in prehistoric ruins in Transylvania. The smelting of zinc ores with copper was apparently discovered in Cyprus and was used later by the Romans. Metallic zinc was produced in the 13th century in India by reducing calamine (zinc carbonate, ZnCO3) with organic substances such as wool. The metal was rediscovered later in Europe. William Champion set up a zinc industry in Bristol (England) in the 1740s.

Approval Year

1921
1447
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8146
Activator
1404
Activator
1404
Hydrolytic Enzyme
38
Target ID: ultraviolet B-induced damage
Interacts
314
Activator
1404
Zinc transporter ZIP1
38
Target ID: Q9NY26
Gene ID: 27173.0
Gene Symbol: SLC39A1
Target Organism: Homo sapiens (Human)
Binding Agent
1037
Zinc transporter ZIP2
38
Target ID: Q9NP94
Gene ID: 29986.0
Gene Symbol: SLC39A2
Target Organism: Homo sapiens (Human)
Binding Agent
1037
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Basic research
Unknown

Approved Use

Unknown
Primary
Approved
8307
CORTROPHIN-ZINC

Approved Use

Treatment of ulcerative colitis and other colonic disorders.

Launch Date

-4.55328006E11
Primary
Preclinical
Unknown

Approved Use

Unknown
Primary
Basic research
Unknown

Approved Use

Unknown
Primary
Basic research
Unknown

Approved Use

Unknown
Secondary
Approved
8307
VORAXAZE

Approved Use

Indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function. Limitation of use: VORAXAZE is not indicated for use in patients who exhibit the expected clearance of methotrexate (plasma methotrexate concentrations within 2 standard deviations of the mean methotrexate excretion curve specific for the dose of methotrexate administered) or those with normal or mildly impaired renal function because of the potential risk of subtherapeutic exposure to methotrexate.

Launch Date

1.32675836E12
Primary
Approved
8307
VUSION

Approved Use

INDICATIONS AND USAGE VUSION Ointment is indicated for the adjunctive treatment of diaper dermatitis only when complicated by documented candidiasis (microscopic evidence of pseudohyphae and/or budding yeast), in immunocompetent pediatric patients 4 weeks and older. A positive fungal culture for Candida albicans is not adequate evidence of candidal infection since colonization with C. albicans can result in a positive culture. The presence of candidal infection should be established by microscopic evaluation prior to initiating treatment. VUSION Ointment should be used as part of a treatment regimen that includes measures directed at the underlying diaper dermatitis, including gentle cleansing of the diaper area and frequent diaper changes.

Launch Date

1.140048E12
Primary
Approved
8307
ZINC OXIDE

Approved Use

Unknown
Primary
Approved
8307
ZINC SULFATE

Approved Use

Unknown

Launch Date

5.47171205E11
Primary
Phase III
651
ZINC SULFATE

Approved Use

Unknown

Launch Date

5.47171205E11
Primary
Phase III
651
ZINC SULFATE

Approved Use

Unknown

Launch Date

5.47171205E11
PubMed

PubMed

TitleDatePubMed
In vitro activity of zinc salts against human rhinoviruses.
1987 Apr
Quadrupolar perturbed 14N NMR in the structurally commensurate and incommensurate phases of ammonium tetrachlorozincate.
1991 Apr 1
Topical zinc oxide treatment increases endogenous gene expression of insulin-like growth factor-1 in granulation tissue from porcine wounds.
1994 Dec
Thujaplicin-copper chelates inhibit replication of human influenza viruses.
1998 Aug
Influence of dietary zinc and copper on digestive enzyme activity and intestinal morphology in weaned pigs.
2006 Dec
Assessing toxicity of fine and nanoparticles: comparing in vitro measurements to in vivo pulmonary toxicity profiles.
2007 May
Glucarpidase (carboxypeptidase g2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy.
2007 Nov
DNA damaging potential of zinc oxide nanoparticles in human epidermal cells.
2009 Mar 28
Difficulty measuring methotrexate in a patient with high-dose methotrexate-induced nephrotoxicity.
2010 Dec
Metal oxide nanoparticles induce unique inflammatory footprints in the lung: important implications for nanoparticle testing.
2010 Dec
In vivo uptake and acute immune response to orally administered chitosan and PEG coated PLGA nanoparticles.
2010 Dec 1
Role of the dissolved zinc ion and reactive oxygen species in cytotoxicity of ZnO nanoparticles.
2010 Dec 15
Oxidative stress, calcium homeostasis, and altered gene expression in human lung epithelial cells exposed to ZnO nanoparticles.
2010 Feb
Glucarpidase following high-dose methotrexate: update on development.
2010 Jan
Engineered nanomaterials cause cytotoxicity and activation on mouse antigen presenting cells.
2010 Jan 12
Phosphorylation of p65 is required for zinc oxide nanoparticle-induced interleukin 8 expression in human bronchial epithelial cells.
2010 Jul
Zinc oxide nanoparticle disruption of store-operated calcium entry in a muscarinic receptor signaling pathway.
2010 Oct
ZnO nanoparticles induce apoptosis in human dermal fibroblasts via p53 and p38 pathways.
2011 Dec
Glucarpidase rescue in a patient with high-dose methotrexate-induced nephrotoxicity.
2011 Jun
High-dose methotrexate-induced renal dysfunction: is glucarpidase necessary for rescue?
2011 Mar 1
Titanium oxide shell coatings decrease the cytotoxicity of ZnO nanoparticles.
2011 Mar 21
Responses of human cells to ZnO nanoparticles: a gene transcription study.
2011 Nov
Zinc induces chemokine and inflammatory cytokine release from human promonocytes.
2011 Nov 30
Safety evaluation of sunscreen formulations containing titanium dioxide and zinc oxide nanoparticles in UVB sunburned skin: an in vitro and in vivo study.
2011 Sep
Zeta potential and solubility to toxic ions as mechanisms of lung inflammation caused by metal/metal oxide nanoparticles.
2012 Apr
Zinc oxide nanoparticles interfere with zinc ion homeostasis to cause cytotoxicity.
2012 Feb
Aerosolized ZnO nanoparticles induce toxicity in alveolar type II epithelial cells at the air-liquid interface.
2012 Feb
Association of zinc ion release and oxidative stress induced by intratracheal instillation of ZnO nanoparticles to rat lung.
2012 Jun 25
Zinc oxide nanoparticles-induced intercellular adhesion molecule 1 expression requires Rac1/Cdc42, mixed lineage kinase 3, and c-Jun N-terminal kinase activation in endothelial cells.
2012 Mar
Molecular cloning, characterization of copper/zinc superoxide dismutase and expression analysis of stress-responsive genes from Eisenia fetida against dietary zinc oxide.
2012 Mar
Glucarpidase for the treatment of life-threatening methotrexate overdose.
2012 Nov
Standard molar enthalpy of combustion and formation of quaternary ammonium tetrachlorozincate [n-CnH2n+1 N(CH3)3]2 ZnCl4.
2013 Dec
Zinc oxide nanoparticles inhibit Ca2+-ATPase expression in human lens epithelial cells under UVB irradiation.
2013 Dec
Sensitivity of human dental pulp cells to eighteen chemical agents used for endodontic treatments in dentistry.
2013 Jan
TiO2, CeO2 and ZnO nanoparticles and modulation of the degranulation process in human neutrophils.
2013 Jul 31
Reactive oxygen species-induced cytotoxic effects of zinc oxide nanoparticles in rat retinal ganglion cells.
2013 Mar
Cytotoxicity in the age of nano: the role of fourth period transition metal oxide nanoparticle physicochemical properties.
2013 Nov 25
Involvement of MyD88 in zinc oxide nanoparticle-induced lung inflammation.
2013 Sep
Mechanism of uptake of ZnO nanoparticles and inflammatory responses in macrophages require PI3K mediated MAPKs signaling.
2014 Apr
Nanosized zinc oxide particles do not promote DHPN-induced lung carcinogenesis but cause reversible epithelial hyperplasia of terminal bronchioles.
2014 Jan
Zinc oxide nanoparticles induce migration and adhesion of monocytes to endothelial cells and accelerate foam cell formation.
2014 Jul 1
Additive effect of zinc oxide nanoparticles and isoorientin on apoptosis in human hepatoma cell line.
2014 Mar 3
Efficacy of glucarpidase (carboxypeptidase g2) in patients with acute kidney injury after high-dose methotrexate therapy.
2014 May
Glucarpidase for the management of elevated methotrexate levels in patients with impaired renal function.
2014 May 15
Immunomodulatory activity of zinc peroxide (ZnO₂) and titanium dioxide (TiO₂) nanoparticles and their effects on DNA and protein integrity.
2014 May 16
Zinc oxide nanoparticles induce apoptosis by enhancement of autophagy via PI3K/Akt/mTOR inhibition.
2014 May 16
ZnO nanoparticles induced adjuvant effect via toll-like receptors and Src signaling in Balb/c mice.
2014 Nov 4
Endoplasmic reticulum stress and oxidative stress are involved in ZnO nanoparticle-induced hepatotoxicity.
2015 Apr 2
Practical considerations for the administration of glucarpidase in high-dose methotrexate (HDMTX) induced renal dysfunction.
2015 Sep
Comparable efficacy with varying dosages of glucarpidase in pediatric oncology patients.
2015 Sep
Patents

Patents

04005147
106
04090844
38
04134847
38
04292237
38
04376079
39
04377675
40
04404196
40
04565693
38
04670586
38
04740363
38
04743435
42
04904401
38
04950702
42
05064815
38
05149745
38
05442047
38
05539121
38
05646324
38
05773011
38
05911978
38
06140331
38
06303833
38
06706904
38
07375243
38
07585885
44
07799339
38
07959530
39
08258190
38
20060128799
38
20060270867
38
20070213331
40
20070249787
39
20080274173
38
20090092554
38
20100048844
38
20100117110
38
20100324259
38
7632959
38
CN105567322
38
EP0119068A1
38
US1767667
38
US20070265374
38
US2522537
38
US2537262
38
US3248354
38
US3453072
38
US3790469
38
US6853140
38

Sample Use Guides

In Vivo Use Guide
single intravenous injection of 50 Units per kg
Route of Administration: Intravenous
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 16 17:43:17 UTC 2022
Edited
by admin
on Fri Dec 16 17:43:17 UTC 2022
Record UNII
KPS085631O
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ZINC SULFIDE
HSDB   INCI   MI  
INCI  
Official Name English
C.I. PIGMENT WHITE 7
Common Name English
ALBALITH
Common Name English
ZINC SULFIDE [INCI]
Common Name English
ZNI 08PB
Common Name English
ZINC MONOSULPHIDE
Common Name English
ZINC(II) SULFIDE
Common Name English
ZINC(II) SULPHIDE
Common Name English
ZINC, THIOXO-
Systematic Name English
ZINC SULFIDE [HSDB]
Common Name English
SACHTOTEC MD 300
Common Name English
C.I. PIGMENT BLACK 17
Common Name English
THIOXOZINC
Systematic Name English
ZINC SULPHIDE
Common Name English
CLEARTRAN
Common Name English
CI-77975
Code English
ZINC SULFIDE [MI]
Common Name English
ZINC MONOSULFIDE
Common Name English
Classification Tree Code System Code
CFR 21 CFR 178.3297
Created by admin on Fri Dec 16 17:43:17 UTC 2022 , Edited by admin on Fri Dec 16 17:43:17 UTC 2022
NCI_THESAURUS C579
Created by admin on Fri Dec 16 17:43:17 UTC 2022 , Edited by admin on Fri Dec 16 17:43:17 UTC 2022
Code System Code Type Description
NCI_THESAURUS
C66694
Created by admin on Fri Dec 16 17:43:17 UTC 2022 , Edited by admin on Fri Dec 16 17:43:17 UTC 2022
PRIMARY
MERCK INDEX
M11630
Created by admin on Fri Dec 16 17:43:17 UTC 2022 , Edited by admin on Fri Dec 16 17:43:17 UTC 2022
PRIMARY Merck Index
MESH
C031238
Created by admin on Fri Dec 16 17:43:17 UTC 2022 , Edited by admin on Fri Dec 16 17:43:17 UTC 2022
PRIMARY
PUBCHEM
9833931
Created by admin on Fri Dec 16 17:43:17 UTC 2022 , Edited by admin on Fri Dec 16 17:43:17 UTC 2022
PRIMARY
EVMPD
SUB32916
Created by admin on Fri Dec 16 17:43:17 UTC 2022 , Edited by admin on Fri Dec 16 17:43:17 UTC 2022
PRIMARY
EPA CompTox
DTXSID7042518
Created by admin on Fri Dec 16 17:43:17 UTC 2022 , Edited by admin on Fri Dec 16 17:43:17 UTC 2022
PRIMARY
RXCUI
1733817
Created by admin on Fri Dec 16 17:43:17 UTC 2022 , Edited by admin on Fri Dec 16 17:43:17 UTC 2022
PRIMARY
ECHA (EC/EINECS)
215-251-3
Created by admin on Fri Dec 16 17:43:17 UTC 2022 , Edited by admin on Fri Dec 16 17:43:17 UTC 2022
PRIMARY
WIKIPEDIA
ZINC SULFIDE
Created by admin on Fri Dec 16 17:43:17 UTC 2022 , Edited by admin on Fri Dec 16 17:43:17 UTC 2022
PRIMARY
FDA UNII
KPS085631O
Created by admin on Fri Dec 16 17:43:17 UTC 2022 , Edited by admin on Fri Dec 16 17:43:17 UTC 2022
PRIMARY
CAS
1314-98-3
Created by admin on Fri Dec 16 17:43:17 UTC 2022 , Edited by admin on Fri Dec 16 17:43:17 UTC 2022
PRIMARY
DAILYMED
KPS085631O
Created by admin on Fri Dec 16 17:43:17 UTC 2022 , Edited by admin on Fri Dec 16 17:43:17 UTC 2022
PRIMARY
HSDB
5802
Created by admin on Fri Dec 16 17:43:17 UTC 2022 , Edited by admin on Fri Dec 16 17:43:17 UTC 2022
PRIMARY
Related Record Type Details
Structure of HYDROGEN SULFIDE
PARENT -> SALT/SOLVATE
Structure of ZINC CATION
PARENT -> SALT/SOLVATE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966